Rule 32, Drugs (Prices Control) Order, 2013: Non–application of the provisions of this order in certain cases
Drugs (Prices Control) Order, 2013 - Rule 32
Text of rule 32
Non–application of the provisions of this order in certain cases
32. Non–application of the provisions of this order in certain
cases.- The provisions of this order shall not apply to, -
(i) a manufacturer producing a new drug patented under the Indian
Patent Act, 1970 (39 of 1970) (product patent) and not produced
elsewhere, if developed through indigenous Research and
Development, for a period of five years from the date of
commencement of its commercial production in the country.
(ii) a manufacturer producing a new drug in the country by a new
process developed through indigenous Research and Development
and patented under the Indian Patent Act, 1970 (39 of 1970)
(process patent) for a period of five years from the date of the
commencement of its commercial production in the country.
(iii) a manufacturer producing a new drug involving a new delivery
system developed through indigenous Research and Development
for a period of five years from the date of its market approval in
India:
Provided that the provision of this paragraph shall apply only when a
document showing approval of such new drugs from Drugs
Controller General (India) is produced before the Government.
Explanation.- Notwithstanding anything contained in this Order, for
the purpose of this paragraph “new drug” shall have the same
so seized, in a court of law and for their safe custody pending such
production; (c) seize any document, such as, cash memo or credit
memo books, books of account and records of purchase and sale of
the drugs in respect of which he suspects that any provision of this
Order has been, is being, or is about to be contravened.
(2) The provisions of Code of Criminal Procedure, 1973 (2 of 1974),
relating to search and seizure shall, so far as may be, apply to
searches and seizures under this Order.
31. Power to review.-— Any person aggrieved by any notification
issued or order made under paragraphs 4, 5 and 6 of this Order,
may apply to the Government for a review of the notification or
order within a period of thirty days of the date of publication of the
notification in the Official Gazette or the receipt of the order by him,
as the case may be, and the Government may make such order on
the application as it may deem proper:
Provided that pending a decision by the Government on the
application submitted under the above paragraph, no manufacturer
shall sell a scheduled formulation or a new drug, as the case may
be, at a price exceeding the ceiling price or retail price, as the case
may be, fixed by the Government of which a review has been
applied for.
32. Non-application of the provisions of this order in certain
cases.- The provisions of this order shall not apply to, -
(i) a manufacturer producing a new drug patented under the Indian
Patent Act, 1970 (39 of 1970) (product patent) and not produced
elsewhere, if developed through indigenous Research and
Development, for a period of five years from the date of
commencement of its commercial production in the country.
(ii) a manufacturer producing a new drug in the country by a new
process developed through indigenous Research and Development
and patented under the Indian Patent Act, 1970 (39 of 1970)
(process patent) for a period of five years from the date of the
commencement of its commercial production in the country.
(iii) a manufacturer producing a new drug involving a new delivery
system developed through indigenous Research and Development
for a period of five years from the date of its market approval in
India:
Provided that the provision of this paragraph shall apply only when a
document showing approval of such new drugs from Drugs
Controller General (India) is produced before the Government.
Explanation.- Notwithstanding anything contained in this Order, for
the purpose of this paragraph “new drug” shall have the same
meaning as is assigned to under rule 122E of the Drugs and
Cosmetics Rules, 1945;
meaning as is assigned to under rule 122E of the Drugs and
Cosmetics Rules, 1945;
[SCHEDULE-I
National List of Essential Medicines 2015
[See paragraphs-2(t), 2(zb)]
(Symbols P, S and T appearing in this Schedule denote essentiality at Primary, Secondary
and Tertiary levels respectively)
Section 1-Anesthetic agents
1.1-General Anesthetics and oxygen
Medicine Level of
Healthcare
Dosage form and strength
1.1.1 Halothane S,T Inhalation
1.1.2 Isoflurane S,T Inhalation
1.1.3 Ketamine P,S,T Injection 10 mg/ml
Injection 50 mg/ml
1.1.4 Nitrous oxide P,S,T Inhalation
1.1.5 Oxygen P,S,T Inhalation (Medicinal gas)
1.1.6 Propofol P,S,T Injection 10 mg/ml
1.1.7 Sevoflurane T Inhalation
1.1.8 Thiopentone P,S,T
Powder for Injection 0.5 g
Powder for Injection 1 g
1.2-Local anesthetics
Medicine Level of
Healthcare
Dosage form and strength
Injection 0.25%
Injection 0.5%
1.2.1
Bupivacaine
S,T
Injection 0.5% with 7.5% glucose
Topical forms 2-5%
Injection 1%
1.2.2 Lignocaine P,S,T Injection 2%
Injection 5% with 7.5% Glucose
1.2.3 Lignocaine (A) +
Adrenaline (B)
P,S,T Injection 1% (A) + 1 :200000 (5
mcg/ml) (B)
Injection 2% (A) + 1 :200000 (5
1.2.4 Prilocaine (A) +
Lignocaine (B)
T Cream 2.5% (A) + 2.5% (B)
1.3-Preoperative medication and sedation for short term procedures
Medicine Level of
Healthcare
Dosage form and strength
1.3.1 Atropine P,S,T Injection 0.6 mg/ml
1.3.2 Glycopyrrolate S,T Injection 0.2 mg/ml
[SCHEDULE-I
National List of Essential Medicines 2015
[See paragraphs-2(t), 2(zb)]
(Symbols P, S and T appearing in this Schedule denote essentiality at Primary, Secondary
and Tertiary levels respectively)
Section 1-Anesthetic agents
1.1-General Anesthetics and oxygen
Lignocaine (B)
Medicine Level of Dosage form and strength
Healthcare
1.1.1 Halothane S,T Inhalation
1.1.2 Isoflurane S,T Inhalation
1.1.3 Ketamine P,S,T Injection 10 mg/ml
Injection 50 mg/ml
1.1.4 Nitrous oxide P,S,T Inhalation
1.1.5 Oxygen P,S,T Inhalation (Medicinal gas)
1.1.6 Propofol P,S,T Injection 10 mg/ml
1.1.7 Sevoflurane T Inhalation
Powder for Injection 0.5 g
P for Injection 1
1.1.8 Thiopentone P,S,T owder for Injection I g
1.2-Local anesthetics
Medicine Level of Dosage form and strength
Healthcare
Injection 0.25%
Injection 0.5%
1.2.1 Bupivacaine S,T Injection 0.5% with 7.5% glucose
Topical forms 2-5%
Injection 1%
1.2.2 Lignocaine P,S,T Injection 2%
Injection 5% with 7.5% Glucose
1.2.3 Lignocaine (A) + P,S,T Injection 1% (A) + 1 :200000 (5
Adrenaline (B) mcg/ml) (B)
Injection 2% (A) + 1 :200000 (5
1.2.4 Prilocaine (A) + T Cream 2.5% (A) + 2.5% (B)
1.3-Preoperative medication and sedation for short term procedures
Medicine Level of Dosage form and strength
Healthcare
1.3.1 Atropine P,S,T Injection 0.6 mg/ml
1.3.2 Glycopyrrolate S,T Injection 0.2 mg/ml
1.3.3 Midazolam P,S,T Tablet 7.5 mg
Tablet 15 mg
Oral liquid 2 mg/ml
Injection 1 mg/ml
Injection 5 mg/ml
1.3.4 Morphine P,S,T Injection 10 mg/ml
Injection 15 mg/ml
Section 2- Analgesics, antipyretics, non steroidal anti inflammatory medicines, medicines used to treat gout and
disease modifying agents used in rheumatoid disorders
2.1- Non-opioid analgesics, antipyretics and no steroidal anti -inflammatory medicines
Medicine Level of
Healthcare
Dosage form and strength
2.1.1 Acetylsalicylicacid P,S,T Tablet 300 mg to 500 mg
Effervescent/ Dispersible/ Enteric
coated Tablet 300 mg to 500 mg
2.1.2 Diclofenac P,S,T Tablet 50 mg
Injection 25 mg/ml
2.1.3 Ibuprofen P,S,T Tablet 200 mg
Tablet 400 mg
Oral liquid 100 mg/5 ml
2.1.4 Mefenamic acid P,S,T Capsule 250 mg
Capsule 500 mg
Oral liquid 100 mg/5 ml
2.1.5 Paracetamol P,S,T Tablet 500 mg
Tablet 650 mg
All licenced oral liquid dosage
forms and strengths
Injection 150 mg/ml
Suppository 80 mg
Suppository 170 mg
2.2-Opioid analgesics
Medicine Level of
Healthcare
Dosage form and strength
2.2.1
Fentanyl S,T Injection 50 mcg/ml
2.2.2 Morphine P,S,T Tablet 10 mg
Injection 10 mg/ml
Injection 15 mg/ml
2.2.3 Tramadol S,T Capsule 50 mg
Capsule 100 mg
Injection 50 mg/ml
2.3-Medicines used to treat gout
Medicine Level of
Healthcare
Dosage form and strength
2.3.1
Allopurinol P,S,T Tablet 100 mg
Tablet 300 mg
2.3.2 Colchicine P,S,T Tablet 0.5 mg
2.4-Disease modifying agents used in rheumatoid disorders
Medicine Level of
Healthcare
Dosage form and strength
2.4.1 Azathioprine S, T Tablet 50 mg
2.4.2 Hydroxychloroquine S,T Tablet 200 mg
Tablet 400 mg
1.3.3 Midazolam P.S,T Tablet 7.5 mg
Tablet 15 mg
Oral liquid 2 mg/ml
Injection 1 mg/ml
Injection 5 mg/ml
1.3.4
Morphine
P,S,T
Injection 10 mg/ml
Injection 15 mg/ml
Section 2- Analgesics, antipyretics, non steroidal anti inflammatory medicines, medicines used to treat gout and|
disease modifying agents used in rheumatoid disorders
2.1- Non-opioid analgesics, antipyretics and no steroidal anti -inflammatory medicines
Medicine Level of Dosage form and strength
Healthcare
2.1.1 Acetylsalicylicacid P,S,T Tablet 300 mg to 500 mg
Effervescent/ Dispersible/ Enteric
coated Tablet 300 mg to 500 mg
2.1.2 Diclofenac P,S,T Tablet 50 mg
Injection 25 mg/ml
2.1.3 Ibuprofen P,S,T Tablet 200 mg
Tablet 400 mg
Oral liquid 100 mg/5 ml
2.1.4 Mefenamic acid P,S,T Capsule 250 mg
Capsule 500 mg
Oral liquid 100 mg/5 ml
2.1.5 Paracetamol P,S,T Tablet 500 mg
Tablet 650 mg
All licenced oral liquid dosage
forms and strengths
Injection 150 mg/ml
Suppository 80 mg
Suppository 170 mg
2.2-Opioid analgesics
Medicine Level of Dosage form and strength
Healthcare
021 Fentanyl S,T Injection 50 mcg/ml
2.2.2 Morphine P,S,T Tablet 10 mg
Injection 10 mg/ml
Injection 15 mg/ml
2.2.3 Tramadol S,T Capsule 50 mg
Capsule 100 mg
Injection 50 mg/ml
2.3-Medicines used to treat gout
Medicine Level of Dosage form and strength
Healthcare
Allopurinol P,S,T Tablet 100 mg
23.1 Tablet 300 mg
2.3.2 Colchicine P,S,T Tablet 0.5 mg
2.4-Disease modifying agents used in rheumatoid disorders
Medicine Level of Dosage form and strength
Healthcare
2.4.1 Azathioprine S, T Tablet 50 mg
2.4.2 Hydroxychloroquine S,T Tablet 200 mg Tablet 400 mg
2.4.3 Leflunomide S,T Tablet 10 mg
Tablet 20 mg
2.4.4 Methotrexate S,T
Tablet 5 mg
Tablet 7.5 mg
Tablet 10 mg
Injection 25 mg/ ml
2.4.5 Sulfasalazine S, T Tablet 500 mg
Section 3-Antiallergics and medicines used in anaphylaxis
Medicine Level of
Healthcare
Dosage form and strength
3.1
Adrenaline P,S,T Injection 1 mg/ml
3.2 Cetirizine P,S,T Tablet 10 mg
Oral liquid 5 mg/5ml
3.3 Chlorpheniramine P,S,T Tablet 4 mg
Oral liquid 2 mg/5 ml
3.4 Dexamethasone P,S,T
Tablet 0.5 mg
3.5 Hydrocortisone P,S,T Powder for Injection 100 mg
3.6 Pheniramine P,S,T Injection 22.75 mg/ml
3.7 Prednisolone P,S,T Tablet 5 mg
Tablet 10 mg
Tablet 20 mg
Oral liquid 5 mg/5 ml
Oral liquid 15 mg/5 ml
Section 4-Antidotes and other substances used in poisoning
4.1- Nonspecific
Medicine Level of
Healthcare
Dosage form and strength
4.1.1 Activated charcoal P,S,T Powder (as licensed)
4.2-Specific
Medicine Level of
Healthcare
Dosage form and strength
4.2.1 Atropine P,S,T Injection 1 mg/ml
4.2.2 Calcium gluconate P,S,T Injection 100 mg/ml
4.2.3 Desferrioxamine S,T Powder for Injection 500 mg
4.2.4 Dimercaprol S,T Injection 50 mg/ml
4.2.5 Methylthioninium
chloride
(Methylene blue)
S,T
Injection 10 mg/ml
4.2.6 N-acetylcysteine P,S,T Sachet 200 mg
Injection 200 mg/ml
4.2.7 Naloxone P,S,T m Injection 0.4 mg/ml
4.2.8 Neostigmine P,S,T Injection 0.5 mg/ml
2.4.3 Leflunomide S,T Tablet 10 mg
Tablet 20 mg
2.4.4 Methotrexate S,T
Tablet 5 mg
Tablet 7.5 mg
Tablet 10 mg
Injection 25 mg/ ml
2.4.5 Sulfasalazine S,T Tablet 500 mg
Section 3-Antiallergics and medicines used in anaphylaxis
Medicine Level of Dosage form and strength
Healthcare
Adrenaline P,S,T Injection 1 mg/ml
3.1
3.2 Cetirizine P,S,T Tablet 10 mg
Oral liquid 5 mg/Sml
3.3 Chlorpheniramine P,S,T Tablet 4 mg
Oral liquid 2 mg/5 ml
3.4 Dexamethasone P,S,T Tablet 0.5 mg
3.5 Hydrocortisone P,S,T Powder for Injection 100 mg
3.6 Pheniramine P,S,T Injection 22.75 mg/ml
3.7 Prednisolone P,S,T Tablet 5 mg
Tablet 10 mg
Tablet 20 mg
Oral liquid 5 mg/5 ml Oral liquid 15 mg/5 ml
Section 4-Antidotes and other substances used in poisoning
4.1- Nonspecific
Medicine Level of Dosage form and strength
Healthcare
4.1.1 Activated charcoal P,S,T Powder (as licensed)
4.2-Specific
Medicine Level of Dosage form and strength
Healthcare
4.2.1 Atropine P.S,T Injection 1 mg/ml
4.2.2 Calcium gluconate P.S,T Injection 100 mg/ml
4.2.3 Desferrioxamine S,T Powder for Injection 500 mg
4.2.4 Dimercaprol S,T Injection 50 mg/ml
4.2.5 Methylthioninium S,T Injection 10 mg/ml
chloride
(Methylene blue)
4.2.6 N-acetylcysteine P,S,T Sachet 200 mg
Injection 200 mg/ml
4.2.7 Naloxone P,S,T m Injection 0.4 mg/ml
4.2.8 Neostigmine P,S,T Injection 0.5 mg/ml
4.2.9 Penicillamine S,T Capsule 250 mg
4.2.10 Pralidoxime
chloride (2- PAM)
P,S,T Injection 25 mg/ml
4.2.11 Snake venom
antiserum
a) Soluble/ liquid
polyvalent
P,S,T
a) Injection
b) Powder for Injection
4.2.12 Sodium nitrite S,T Injection 30 mg/ml
4.2.13 Sodium
S,T Injection 100 mg/ml
Section 5-Anticonvulsants/Antiepileptics
Medicine Level of
Healthcare
Dosage form and strength
5.1 Carbamazepine P,S,T Tablet 100 mg
Tablet 200 mg
CR Tablet 200 mg
Tablet 400 mg
CR Tablet 400 mg
Oral liquid 100 mg/5 ml
Oral liquid 200 mg/5 ml
5.2 Clobazam S,T Tablet 5 mg
Tablet 10 mg
5.3 Diazepam P,S,T
Oral liquid 2 mg/5 ml
Injection 5 mg/ml
Suppository 5 mg
5.4 Levetiracetam S,T Tablet 250 mg
Tablet 500 mg
Tablet 750 mg
ER Tablet 750 mg
Oral liquid 100 mg/ml
Injection 100 mg/ml
5.5 Lorazepam P,S,T Tablet 1 mg
Tablet 2 mg
Injection 2 mg/ml
5.6 Magnesium
sulphate
S,T Injection 500 mg/ml
5.7 Phenobarbitone P,S,T Tablet 30 mgTablet 60 mgOral
liquid 20 mg/5 ml
S,T Injection 200 mg/ml
5.8 Phenytoin P,S,T Tablet 50 mg
Tablet 100 mg
Tablet 300 mg
ER Tablet 300 mg
Oral liquid 30 mg/5 ml
Oral liquid 125 mg/5 ml
Injection 25 mg/ml
Injection 50 mg/ml
5.9 Sodium valproate P,S,T Tablet 200 mg
Tablet 300 mg
CR Tablet 300 mg
Tablet 500 mg
CR Tablet 500 mg
Oral liquid 200 mg/5ml
T Injection 100 mg/ml
Section 6-Anti infective medicines
6.1-Anthelminthics
6.1.1-Intestinal anthelminthics
4.2.9 Penicillamine S,T Capsule 250 mg
4.2.10 Pralidoxime
chloride (2- PAM)
P,S,T Injection 25 mg/ml
4.2.11 Snake venom
antiserum
a) Soluble/ liquid
polyvalent
P,S,T a) Injection
b) Powder for Injection
4.2.12 Sodium nitrite S,T Injection 30 mg/ml
4.2.13 Sodium S,T Injection 100 mg/ml
Section 5-Anticonvulsants/Antiepilepti CS
Medicine Level of
Healthcare
Dosage form and strength
5.1 Carbamazepine P,S,T Tablet 100 mg
Tablet 200 mg
CR Tablet 200 mg
Tablet 400 mg
CR Tablet 400 mg
Oral liquid 100 mg/5 ml
Oral liquid 200 mg/5 ml
5.2 Clobazam S,T Tablet 5 mg
Tablet 10 mg
5.
Previous and next
Questions people ask
Is rule 32 of Drugs (Prices Control) Order, 2013 still in force?
No repeal of Drugs (Prices Control) Order, 2013 is recorded.